The participants will be pregnant women with late-onset pre-eclampsia

Pre-Eclampsia

On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).

Placental growth factor

Alex Ekwuueme Federal University Teaching Hospital

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women in Abakaliki

Adverse maternal outcomes will include one or more of: disseminated intravascular coagulation (DIC), HELLP syndrome, abruptio placentae, pulmonary oedema, intracerebral haemorrhage, acute left ventricular failure, renal insufficiency (creatinine >90 umol/l), liver disease (aspartate aminotransferase >40 U/l), eclampsia and maternal death.

Adverse fetal outcomes will include one or more of: Apgar score <7 at the 5th minute, small-for-gestational-age infant (SGA; <10th centile), admission to special-care nursery, fetal death and early neonatal death.

The researchers plan to make the data available to other authors

Johnbosco Ifunanya Nwafor

Principal investigator

After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.
Control group will be treated with placebo.

50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.

Severe Pre-eclampsia

Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.

Rosuvastatin

Placebo

Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery

Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery

systolic pressure below 140mm\Hg or diastolic pressure below 90mm\Hg. Measurement will be carried out according to standard Protocol: before delivery, every 30 minutes during the first 2 hours post-delivery then every hour until discharge.

We intend to test the following metrics:
The amount and activity of NK cells in the placenta.
The rate of secretion of angiogenic factors VEGF, SFLT-1, PLGF and inflammation factors TGF-ALFA I and IL-6.

Ofer Beharier

Physician at Obstetrics and Gynecology Division

Soroka University Medical Center

Apheresis for extracorporal removal of sFlt-1

Preeclampsia

CHIC

Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia

Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation

During the first step (inclusion of 8 patients) analysis is done continuously, and if 3 women have unsuccess primary endpoint, first step and the study are stopped, with a conclusion of failure of the procedure of lipapheresis.

The data will be measured during the participation of the patient : 15 weeks = 11 weeks of pregnancy monitoring (from 23 to 34 weeks' gestation) + 4 weeks postpartum

A description of the following variables will be used: blood pressure during the session, infectious or hemorrhagic events subsequent infusion and / or technique. The time frame is 11 weeks as a maximum : 11 weeks of pregnancy monitoring (from 23 to 34 weeks' gestation)

Measuring of the heart monitoring's data will be used. The time frame is 11 weeks as a maximum : 11 weeks of pregnancy monitoring (from 23 to 34 weeks' gestation)

For the measure of the maternal adsorptive efficiency, the following parameters will be described: circulating levels of sFlt1, the placental growth factor (PlGF) and soluble endoglin (sEng). The time frame is 12 weeks : 11 weeks of pregnancy monitoring (from 23 to 34 weeks' gestation) + until deliverance

Assistance Publique - Hôpitaux de Paris

Gastrointestinal Stromal Tumors

imatinib mesylate

J Clin Oncol 30, 2012 (suppl; abstr e20514) (From 2012 ASCO Annual Meeting )

See results for CSTI571BIC08 at Novartis Clinical Trials Database

Novartis Investigative Site

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)

pulmonary edema/tyrosine

Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women

Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery

Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen